Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
Article content
SAN DIEGO and TORONTO, May 14, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today announced that data from its Phase 1/2 TUSCANY trial in newly diagnosed patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) has been selected for oral presentation at the European Hematology Association Congress (EHA 2025), being held June 12-15, 2025, in Milan, Italy.
Article content
The TUS+VEN+AZA triplet is being developed as the only safe and mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. As reported prior, the first two dose cohorts at 40 mg of TUS or 80 mg of TUS in the TUS+VEN+AZA triplet, have demonstrated safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients. The oral presentation at EHA will include updated safety, complete remission, minimal residual disease (MRD) clinical findings, and longer duration of follow-up.
Article content
Details of the presentation are as follows:
Title: TUSCANY Study of Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy
Session: Oral Presentations: Acute Myeloid Leukemia – Clinical
Session Date and Time: Thursday, June 12, 2025, 5:00 – 6:15 pm CEST
Presenter: Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine
Abstract #: S139
Article content
Article content
The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 clinical study with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. Earlier APTIVATE trials of TUS as a single agent and in combination as TUS+VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Indeed, responses were also in R/R AML patients with highly adverse TP53 and RAS mutations, and those with mutated or unmutated (wildtype) FLT3 genes.
Article content
The TUSCANY Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by mid-late 2025. Data will be released as it becomes available.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
3 days ago
- Toronto Star
Ninepoint Publishes 2025 Midyear Outlook for Investing
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) — Ninepoint Partners LP ('Ninepoint'), one of Canada's leading independent investment management firms, today released its 2025 Midyear Market Outlook, offering insights across key asset classes including fixed income, private equity, energy, gold, crypto and infrastructure. The report reflects on a volatile first half of the year, marked by macroeconomic uncertainty and the impact of U.S. tariffs, and looks ahead to what investors can expect in the second half of 2025 and beyond.
National Post
5 days ago
- National Post
Anaergia S.r.l. to Supply Capital Equipment for Co-Digestion to Biomethane System in Livorno, Italy
Article content First Co-Digestion System in Italy Will Combine Source-Separated Organics and Wastewater Article content Article content TREVIGLIO, Italy & BURLINGTON, Ontario — Anaergia Inc. ('Anaergia', the 'Company', 'us', or 'our') (TSX:ANRG; OTCQX:ANRGF), through its subsidiary, Anaergia S.r.l., entered into a binding agreement with RDR S.p.A. ('RDR'), a leading Italian engineering and construction firm, that has been awarded a public tender by ASA Livorno, operator of the municipal wastewater treatment plant in the City of Livorno, Tuscany. Article content Anaergia is to supply capital equipment for the Livorno facility, enabling the plant to co-digest food waste and other source-separated organics ('SSO') with wastewater sludge to produce renewable biomethane. This project is to be Italy's first facility to combine these streams for biogas production. Article content Construction is already underway, with the system expected to be fully operational by December 2026. The total investment in this project is to be approximately C$25 million, and Anaergia expects to recognize revenues of C$3.2 million. Article content 'We are pleased to be partnering with Anaergia on this groundbreaking project for ASA Livorno,' said Francesco Freddo, Head of Commercial Department of RDR. 'Anaergia's proven experience in anaerobic digestion and its expertise in co-digesting organics with wastewater sludge make it the ideal technology partner for this innovative system.' Article content 'While Anaergia's long-standing experience in Italy and in co-digestion globally is well established, we're especially excited to deliver Italy's very first co-digestion plant,' stated Assaf Onn, CEO of Anaergia. 'Leveraging our global expertise with our proven solutions, this project exemplifies how we turn complementary waste streams into valuable energy resources, helping Livorno, and the planet, move toward a sustainable future.' Article content About ASA Livorno Article content ASA Livorno is a utility providing integrated water services in the Province of Livorno, in the Region of Tuscany. ASA Livorno is part of Azienda Servizi Ambientali S.p.A ('ASA'), an integrated water service provider and gas distributor, which considers water resources and methane gas to be fundamental assets for life and the development of the planet. In order for these resources to be available in adequate quantities for future generations, the company works to optimize the efficiency and the effectiveness of the processes it utilizes. Article content For additional information on ASA, please see: About RDR RDR S.p.A., is a leader in the integrated water sector, specializing in the design, construction, management, maintenance and commissioning of aqueduct works and of water treatment plants. RDR's Plant Design and Construction Division benefits from considerable experience, acquired over the years of activity and it is able to provide a wide range of services to meet specific customer needs. Article content For additional information on RDR please see: About Anaergia Anaergia is a pioneering technology company in the renewable natural gas (RNG) sector, with over 250 patents dedicated to converting organic waste into sustainable solutions such as RNG, fertilizer, and water. We are committed to addressing a significant source of greenhouse gases (GHGs) through cost-effective processes. Our proprietary technologies, combined with our engineering expertise and vast experience in facility design, construction, and operation, position Anaergia as a leader in the RNG industry. With a proven track record of delivering hundreds of innovative projects over the past decade, we are well-equipped to tackle today's critical resource recovery challenges through diverse project delivery methods. As one of the few companies worldwide offering an integrated portfolio of end-to-end solutions, we effectively combine solid waste processing, wastewater treatment, organics recovery, high-efficiency anaerobic digestion, and biomethane production. Additionally, we operate RNG facilities owned by both third parties and Anaergia. This comprehensive approach not only reduces environmental impact but also significantly lowers costs associated with waste and wastewater treatment while mitigating GHG emissions. Article content For additional information on Anaergia please see: Forward-Looking Statements This news release contains forward-looking information within the meaning of applicable securities legislation, which reflects Anaergia's current expectations regarding future events, including but not limited to, counterparty contractual performance, and the capability of the Company's technology and performance with respect to the project objectives. Forward-looking information is based on a number of assumptions, including, but not limited to counterparty contractual performance, the timing of construction of the new facility, the expected volume of SSO, the expected production of biomethane, the total investment and expected revenues of the project, the capability of the Company's technology and performance with respect to the project objectives, and the sufficient sourcing of food waste and power generation. The Company is subject to a number of risks and uncertainties, many of which are beyond the Company's control. Such risks and uncertainties include, but are not limited to, the factors discussed under 'Risk Factors' in the Company's annual information form for the fiscal year ended December 31, 2024, and under 'Risks and Uncertainties' in the Company's most recent management's discussion and analysis. Actual results could differ materially from those projected herein. Anaergia does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws. Additional information on these and other factors that could affect Anaergia's operations or financial results are included in Anaergia's reports on file with Canadian regulatory authorities. Article content Article content
Toronto Star
27-06-2025
- Toronto Star
Homegrown Loyalty Surges Ahead of Canada Day
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) — As the country prepares to celebrate Canada Day, new research from Horizon Media Canada confirms a powerful consumer shift toward local loyalty—one that is reshaping purchase behaviour across provinces and generations. According to the firm's latest Finger on the Pulse survey, 83 per cent of Canadians say buying local evokes a sense of national pride, and 71 per cent report being more loyal to Canadian brands in 2025 than they were a year ago. Conducted in April with a nationally representative sample of more than 1,000 adults, the survey finds that Canadians are responding to economic uncertainty, rising tariffs and a weaker dollar by making more intentional, values-based choices at checkout.
